Platinum complexes remain widely used to combat various types of cancers. Three platinum complexes, cisplatin, carboplatin and oxaliplatin, are marketed for various oncological purposes. Additionally, nedaplatin, lobaplatin and heptaplatin have gained regionally limited approval for oncology purposes. Furthermore, various platinum derivatives are currently under clinical trials. More than 40 ye...

a-Amino Acid Esters, Peptide Esters, Platinum(IV) Complexes, "N NMR Spectra, Pt NMR Spectra The platinum(IV) complexes PtX4L2 (X = Cl, Br; 2 X = oxalate; L = glyOEt, glyglyOEt, gly-cleuOEt; 2 L = metOEt) have been obtained by oxidative addition of halogenes to platinum(II) compounds PtX2L2A high field shift of <3N (—50 ppm) is observed for the coordinated amino acid ligand of various platinum c...

Five oxaliplatin-typed platinum complexes containing trans-1R, 2R-diaminocyclohexane chelating platinum cores, characteristic of linear or branched alkoxycarboxylates as leaving groups, were biologically evaluated. These compounds showed higher antitumor activity, lower toxicity in vivo than cisplatin or oxaliplatin. And the results revealed that the antitumor activity and interaction with DNA ...

Gene expression profiling of tumors allows the establishment of relationships between gene expression profiles and sensitivity to anticancer drugs. In an attempt to study the molecular determinants of the activity of platinum compounds, we explored the publicly available databases of the National Cancer Institute (NCI; http://dtp.nci.nih.gov), which allow access to the gene expression profiles ...

Gene expression profiling of tumors allows the establishment of relationships between gene expression profiles and sensitivity to anticancer drugs. In an attempt to study the molecular determinants of the activity of platinum compounds, we explored the publicly available databases of the National Cancer Institute (NCI; http://dtp.nci.nih.gov), which allow access to the gene expression profiles ...

INTRODUCTION CISPLATIN has been shown to have some activity in gastric cancer but its application is limited because of toxicity [ 11. In recent years, the search for platinum compounds with reduced toxicity has been the main goal in the development of platinum analogs. Based on available phase I data [2, 31, our group decided to evaluate the antitumor activity of the non-nephroand neurotoxic p...

The Electrosynthesis of Organic Compounds Measurement of Electrodeposit Thickness Electron Concentration as a Guide to Alloying Behaviour A Rhodium-Platinum Probe for Flame Velocity Measurement Ruthenium-Platinum Oxide Catalysts for Hydrogenation Reactions Complexes of Substituted Olefins with Salts of the Platinum Metals Making Corrosion-Resistant Brazed Joints in Stainless Steel Thermocouples...

Hypoxia in solid tumors remains a challenge for conventional cancer therapeutics. As a source for resistance, metastasis development and drug bioprocessing, it influences treatment results and disease outcome. Bioreductive platinum(iv) prodrugs might be advantageous over conventional metal-based therapeutics, as biotransformation in a reductive milieu, such as under hypoxia, is required for dru...

Newly synthesized phthalazine derivatives including copper and platinum complexes were evaluated for cytotoxicity in human breast cancer cell lines. The cells were incubated with the compounds (100 microM) for 72 h and cytotoxicity, apoptosis and DNA content were measured by flow cytometery. Our results suggest that the parent (H1-2), copper (C1-2)- and platinum (P1-2)-derivatized compounds wer...

To discover whether novel anti-tumor platinum agents are capable of selectively accumulating in tumor tissue, three novel potassium N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxylhex-1-yl]-L-amino acid dichloroplatinates(II) were prepared. At a dose of 1.67 μmol kg(-1) the in vivo anti-tumor potencies of two of the compounds were higher than that of oxaliplatin. The mortality analysis indicated that t...